[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | Sponsor | E-mail ]

Turkish Journal of Cancer
1994, Volume 24, Number 3, Page(s) 147-156
[ Summary ]
5-Fluorouracil, adriamycin and mitomycin-C combination chemotherapy for advanced gastric carcinoma
İBRAHİM GÜLLÜ, GÜLTEN TEKUZMAN, EŞMEN BALTALI, İBRAHİM BARIŞTA, AYŞE KARS, NİLÜFER GÜLER, GÖRGÜN AKPEK, DİNÇER FIRAT
Hacettepe University Institute of Oncology, Ankara-Turkey

A phase II trial of the combination of 5-fluorouracil, adriamycin and mitomycin-C (FAM) was conducted in 40 patients with gastric carcinoma. Patients had not received chemotherapy previously and had measurable advanced disease. There were four complete responses and ten partial remissions (overall response rate of 35%, with confidence limits of 21%-49% for a confidence level of 95%). Duration of response ranged between 3 and 26 months. The overall median survival was 13 months (5-32+). There was a significant difference between the survival rates of responding and nonresponding patients (p=0.002). Sex, localization and histopathologic differentiation of tumor were not found to be important prognostic discriminants. Only initial performance status (PS) appeared to be an important prognostic factor for survival (p=0.016). Toxicity was generally mild to moderate, and in only a few patients was it necessary to reduce the drug doses or to prolong the intervals between cycles. These results show that patients with advanced gastric cancer can be effectively palliated with FAM chemotherapy, and this regimen is comparable to high dose aggressive new chemotherapy regimens.

[ Summary ]
Turkish Journal of Cancer web sitesi Novartis Onkoloji'nin karşılıksız eğitim katkılarıyla hazırlanmıştır.
[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | E-mail ]